Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.49 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.49 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.49 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20211706 | 0.86 | GUCY1B2 (0.56) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16906964 | 0.85 | PDE5A (0.53) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL17616791 | 0.79 | PDE5A (0.53) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL17611011 | 0.78 | PDE5A (0.57) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL15087569 | 0.78 | GUCY1B2 (0.64) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082641 | 0.78 | GUCY1B2 (0.56) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL23639455 | 0.77 | GUCY1A1 (0.44) | GUCY1A1GUCY1B1 | |
| SCHEMBL17618950 | 0.77 | GUCY1B2 (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16907013 | 0.77 | GUCY1B2 (0.60) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16907047 | 0.76 | GUCY1B2 (0.61) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | disclosed |